Context Therapeutics Reports Positive Interim Phase 1a Data for CTIM-76 and Extends Cash Runway
CNTX has more than doubled off its 52-week low of $0.49 on elevated volume (2.3× avg).
Summary
Context Therapeutics updated its corporate presentation, revealing positive interim Phase 1a data for its lead T-cell engager, CTIM-76, including a confirmed partial response in platinum-resistant ovarian cancer, and announced an extended cash runway into 2027.
Key Events · Product Development and Regulatory · CNTX
-
Positive CTIM-76 Phase 1a Data
Interim Phase 1a data for CTIM-76 showed a confirmed partial response with an 85% tumor reduction in a patient with platinum-resistant ovarian cancer who had progressed on prior therapy. No cytokine release syndrome greater than Grade 1 or dose-limiting toxicities were observed.
-
Extended Cash Runway
The company announced an expected cash runway into 2027, providing financial stability for ongoing clinical development and operations.
-
Pipeline Advancement
Updates were provided for CT-95, with initial Phase 1a data anticipated mid-2026, and CT-202, with regulatory filings for its first-in-human trial expected in Q2 2026, showcasing active pipeline progression.
Analysis · CNTX · Life Sciences
The updated corporate presentation highlights significant progress in Context Therapeutics' pipeline, particularly with CTIM-76. The confirmed partial response in a heavily pre-treated patient with platinum-resistant ovarian cancer from the Phase 1a trial is a strong early clinical signal, suggesting the drug's potential efficacy. This positive data, combined with an extended cash runway into 2027, provides a more stable financial outlook and de-risks the company's lead program. Investors should monitor further clinical developments for CTIM-76 and the progression of CT-95 and CT-202.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.9% of the 1050 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTX was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $152.5M. The 52-week trading range was $0.49 to $2.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.